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Cystic fibrosis (CF) is an inherited chronic life-threatening 
disease that most critically affects the lungs. It causes the produc-
tion ofsticky mucus that clogs the lungs and leads to inflammation. 
The severity of lung damage determines the evolution of the disease 
and requires instrumental confirmation.
Research was performed to determinate the structural changes 
of the lung tissue in children with CF by the conventional chest 
X-ray and thorax spiral computed tomography (CT).
In this study we evaluated the chest X-raysof 55 patients (32 
girls and 23 boys) and the CT scans of 36 patients with CF (21 
girls and 15 boys), from 2 to 18 years. Four patients had a mild 
evolution of CF, 10 children had moderate, and 21 suffered from 
the severe form of the disease.
The most common chest radiographic findings in CF patients 
were hyperinflation (87.3%), bronchial thickening (94.5%) and 
dilatation (41.8%), an increase in interstitial markings (76.3%), 
and pneumofibrosis (85.4%).
Abnormal findings were detected in 94.4% patients examined 
by CT. Bronchiectasis developed in 77.7% CF patients, including 
28.6% cases in the upper or mid lobes and 71.4% children with gen-
eralized bronchiectasis. Cysticbronchus deformations withliquid 
levels were identified in 2 of the patients with severe evolution of 
CF. Sectors of fibrosis were revealed in 6 spiral CT images. In two 
of the CF children CT findings of chronic obstructive bronchitis 
were detected, and in other two patients no structural bronchial 
changes were founded.
The method of spiral tomography offeredmore complete and 
detailed information about the anatomo-morphological substrate 
of pulmonary modifications in children with cystic fibrosis.
In children with CF structural bronchopulmonaryspiral 
CTsreveals modificationssuch as focal fibrosis, and sometimes 
widespread bronchial deformations with saccate bronchiectasis.
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levels and bronchial asthma phenotype in schoolchildren (χ2=22,2, 
p<0,001). The phenotype of virus-induced, effort induced and 
unresolved asthma is clinically presented by mild symptoms. Al-
lergen-induced asthma is dominated by severe forms of the disease. 
Phenotype allergen-induced asthma is identified in 70% of 
children included in the present study and is characterized by 
high levels of the total serum IgE. The low values of total IgE in 
children with virus-induced, effort induced and unresolved asthma 
demonstrates the implication of slow allergic reactions. 
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Bronchiolitis is swelling and mucus buildup in the smallest air 
passages in the lungs (bronchioles) usually due to a viral infection 
(RSV, adenovirus, influenza, Parainfluenza). Bronchiolitis usually 
affects children under the age of 2, with a peak in the age of 3 - 6 
months. It is a common, and sometimes severe illness. 
Risk factors for bronchiolitis include: exposure to cigarette 
smoke at an age younger than 6 months old, living in crowded 
conditions, not being breastfed, and prematurity. Sometimes, no 
treatment is necessary.
The basic management of typical bronchiolitis is anchored 
in the provision of therapies that assures the patient is clinically 
stable, well oxygenated, and well hydrated. The main benefits of 
hospitalization of infants with acute bronchiolitis are the careful 
clinical monitoring, maintenance of a patent’s airway (through 
positioning, suctioning, and mucus clearance) and adequate hy-
dration, and parental education.
It is recommended to consider monitoring the cardiac and 
respiratory rate in hospitalized patients during the acute stage of 
bronchiolitis when the risk of apnea and/or bradycardia is greatest: 
premature infants, infants with underlying chronic conditions 
predisposing to apnea, infants with a witnessed episode of apnea, 
and infants less than three months of age who contract RSV.
It is recommended to administer supplemental oxygen when 
the saturation is less than 91% and consider weaning oxygen when 
the saturation is higher than 94%.
Systemic corticosteroids and inhaled bronchodilators are wide-
ly used by clinicians caring for infants with bronchiolitis. Clinical 
practice guidelines have recommended against their routine use, 
although there may be some instances where they will be useful: 
in older patients (> 12 months) with asthma risk factors (parental 
history of asthma, in utero exposure to parental smoking, and 
repeated wheezing before age 1) and any history of wheezing. It 
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is recommended that a single trial inhalation using epinephrine 
or albuterol is to be considered on an individual basis.
Nebulized racemic epinephrine demonstrates better short-
term improvement in pulmonary physiology. Combined treatment 
of systemic glucocorticoids (dexamethasone) and bronchodilators 
(epinephrine) may significantly reduce hospital admissions.
It is recommended the infant be suctioned, when clinically in-
dicated before feedings, as needed, prior to each inhalation therapy 
and normal saline nose drops may be used prior to suctioning. 
Current guidelines do not recommend routine chest physiotherapy 
in the management of bronchiolitis.
Infants with this severe disease may need supportive care for 
respiratory failure and dehydration, such as mechanical ventilation 
and supplemental fluid therapy. Treatment for severe bronchiolitis 
may include: humidified oxygen therapy, chest physical therapy, 
bronchodilator medications: Ventolin, Salbutamol, Epinephrine 
(Adrenalin), anti-viral medication from bronchiolitis: ribavirin, 
palivizumab, antibiotics for associated otitis media, suspected 
bacterial pneumonia, and mechanical ventilation.
It is recommended that the family be educated on the following 
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Cystic fibrosis (CF) is a life-shortening genetic disease cha-
racterized by variability in the age of death. This is largely due to 
variability in the rate of progression of lung disease, the primary 
cause of mortality. In most patients with cystic fibrosis (CF) life 
expectancy is limited due to a progressive loss of functional lung 
tissue. 80% of premature deaths continue to result directly or 
indirectly from loss of lung function. 
The factors associated with an increased risk of lung disease 
progression are: young age, high lung function, being of the fe-
male sex, certain CFTR genotypes, pancreatic insufficiency, poor 
nutritional status, lower socioeconomic status, respiratory viral 
infections, and infection of Pseudomonas aeruginosa or Burkhol-
deria cepacia.
 Virtually all patients with CF are chronically infected with one 
or more bacterial species, and the inflammatory response to infec-
tion appears to be more intense in patients with CF. Early infection 
of CF in the airways is mostly caused by Staphylococcus aureus and 
Haemophilus influenza, than from P. aeruginosa or other gram 
negative stains. Recent studies, especially those following patients 
diagnosed by neonatal screening, have shown that infection of P. 
aeruginosa usually occurs at very young age. Positive antibody 
response to P. aeruginosa was found in children, with the mean age 
of 15 months, about 12 months before first cultures were positive. 
Also in young, non-sputum producing children it was found that 
throat swabs frequently showed positive cultures for P. aeruginosa. 
Chronic infection is prevalent in about 80% of all patients with 
CF. In patients with chronic infection and alginate-coated mucous 
strains of Ps. aeruginosa, eradication is nearly impossible. CF and 
Ps. aeruginosa, an unfavorable relationship, can be explained by the 
possibility of CFTR acting as a specific receptor for Ps. aeruginosa. 
CFTR may influence bacterial adherence to epithelial cells. The 
“overproduction” of pro-inflammatory cytokines and significantly 
lower levels of the anti-inflammatory cytokine IL-10, which in-
hibits the production of pro-inflammatory cytokines, results in 
excessive and persistent inflammation in the CF airways. As a 
result, lung functioning deteriorates more rapidly in Ps. aerugi-
nosa-positive CF patients compared with Ps. aeruginosa-negative 
CF patients. Patients with cystic fibrosis are often colonized with 
bacteria other than PA, causing bronco-pulmonary infections that 
lead to the deterioration of lung functioning such as: Burkholderia 
cepacia complex, Achromobacter xylosoxidans and Stenotrophomo-
nas maltophilia. Patients chronically infected with S. maltophilia 
are cable of rising a specific antibody response against this bacteria 
associated with worsening lung function. Chronic infection of S. 
maltophilia is correlated with a decline in lung functioning, but this 
decline was already present prior to the chronic infection, where 
the high prevalence of Aspergillus and ABPA and NTM may have 
contributed a role in this result. 
Staphylococcus aureus (S. aureus) is one of the earliest bacteria 
detected in infants. Treatment with anti-staphylococcal agents 
reduces the infection rate of MSSA but may lead to a higher rate 
of infection of Ps. aeruginosa. S. aureus which isolates harbor to 
a multitude of virulence factors, overlapping to a large degree in 
MSSA and MRSA. To date there are no conclusive studies demon-
strating that the early aggressive treatment of MRSA respiratory 
infection can prevent chronic infection or if this approach ulti-
mately improves outcomes.
Key words: cystic fibrosis, pulmonary infection, lung disease.
topics regarding the care of a child with bronchiolitis: to call their 
primary care provider if the following signs of worsening clinical 
status are observed: increasing respiratory rate and/or work of 
breathing as indicated by use of the accessory muscle, inability to 
maintain adequate hydration, or worsening general appearance.
Therapies NOT Routinely Recommended:
It is recommended that scheduled or serial inhalation thera-
pies not be used routinely nor repeated if there is no measured 
improvement in the clinical outcome after a trial inhalation. 
Hypertonic saline inhalations are not to be given for the routine 
treatment of bronchiolitis due to inconsistent evidence regarding 
its effectiveness. It is recommended at this time that the following 
drugs not be used in the treatment of bronchiolitis: antibodies 
(immunoglobulins), Montelukast, Recombinant human deoxy-
ribonuclease (rhDNase), antihistamines, oral decongestants, and 
nasal vasoconstrictors. Antibiotics are not recommended unless 
bacterial infection is suggested (e.g., toxic appearance, hyperpy-
rexia, consolidation or focal lobar infiltrates on chest radiograph, 
leukocytosis, positive bacterial cultures).
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